Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.72 |
| ▸ | FGFR4 | P22455 | 10/20 | 0.72 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.72 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.72 |
| ▸ | FGFR3 | P22607 | 5/20 | 0.72 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.72 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.72 |
| ▸ | KDR | P35968 | 3/20 | 0.72 |
| ▸ | FYN | P06241 | 2/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
| ▸ | EPHB3 | P54753 | 2/20 | 0.72 |
| ▸ | PRKACA | P17612 | 1/20 | 0.61 |
| ▸ | PRKACG | P22612 | 1/20 | 0.61 |
| ▸ | PRKACB | P22694 | 1/20 | 0.61 |
| ▸ | CSF1R | P07333 | 2/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5772117 | 0.95 | EGFR (0.74) | EGFRFGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL5772112 | 0.95 | EGFR (0.74) | EGFRFGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL5768936 | 0.91 | FGFR4 (0.80) | EGFRFGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL5770073 | 0.90 | EGFR (0.76) | EGFRFGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL5770003 | 0.90 | FGFR4 (0.79) | EGFRFGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL5745949 | 0.85 | EGFR (0.72) | EGFRFGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL5831546 | 0.85 | EGFR (0.90) | EGFRFGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL5767242 | 0.85 | EGFR (0.76) | EGFRFGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL5767065 | 0.85 | EGFR (0.90) | EGFRFGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL5767330 | 0.85 | EGFR (0.73) | EGFRFGFR4FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115740-B2 | Pyrimido compounds having antiproliferative activity | HOFFMANN-LA ROCHE INC. (US) | 2006-10-03 | — | — | US | claimed |
| EP-1615928-A1 | PYRIMIDO COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-18 | — | — | EP | claimed |
| WO-2004089955-A1 | PYRIMIDO COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-10-21 | — | — | WO | claimed |
| US-20040204427-A1 | Pyrimido compounds having antiproliferative activity | CHEN YI (US) | 2004-10-14 | — | — | US | claimed |
| US-7115740-B2 | Pyrimido compounds having antiproliferative activity | HOFFMANN-LA ROCHE INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1615928-A1 | PYRIMIDO COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089955-A1 | PYRIMIDO COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204427-A1 | Pyrimido compounds having antiproliferative activity | CHEN YI (US) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204427-A1 | Pyrimido compounds having antiproliferative activity | FGFR3, FGFR1, FGFR4 | EGFR 41/4885FGFR4 3/4885FGFR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.